Oncology nursing

OVARIAN CANCER RESEARCH ALLIANCE LAUNCHES INNOVATIVE "FIND A DOCTOR" TOOL TO EMPOWER PATIENTS NATIONWIDE

Retrieved on: 
Tuesday, April 9, 2024
Komodo, Diagnosis, Ovarian cancer, Database, Patient, Research, Oncology, Oncology nursing, Ovary, OCRA, Clinical trial, Geography, Ovarian Cancer Research Alliance, Physician, Birth control

NEW YORK, April 9, 2024 /PRNewswire/ -- Today, Ovarian Cancer Research Alliance (OCRA) proudly unveiled its latest innovation in supporting individuals affected by ovarian and other gynecologic cancers: the "Find a Doctor" tool.

Key Points: 
  • NEW YORK, April 9, 2024 /PRNewswire/ -- Today, Ovarian Cancer Research Alliance (OCRA) proudly unveiled its latest innovation in supporting individuals affected by ovarian and other gynecologic cancers: the "Find a Doctor" tool.
  • Navigating a diagnosis of ovarian or other gynecologic cancer can be overwhelming, and finding the right medical team is paramount to ensuring the best possible outcomes.
  • "Access to quality care is a critical issue of equity for patients," said Audra Moran, President and CEO of OCRA.
  • The new tool underscores OCRA's ongoing commitment to advancing research, raising awareness, and providing support to the ovarian cancer community.

2024 Oncology Nurse Advisor Summit Shatters Attendance Records

Retrieved on: 
Wednesday, April 3, 2024
Oncology, Nursing, Education, Health, Continuing, Training, Diagnosis, RN, MHA, Inclusion, NACE, CPPS, Faculty, NSCLC, Real, ONA, American Cancer Society, Knowledge, DNP, Accreditation, Oncology nursing, AANP, Merck, Fox Chase Cancer Center, Bristol Myers Squibb, Oncology Nursing Certification Corporation, MSN, ANCC, Johnson & Johnson, Merck & Co., Summit, National Association, Hematology, Skin cancer, HMN, HME

Over 2,200 attendees enriched their knowledge in disease-specific and supportive care topics during the 9th Annual Oncology Nurse Advisor (ONA) Summit, which occurred from March 21-24, 2024.

Key Points: 
  • Over 2,200 attendees enriched their knowledge in disease-specific and supportive care topics during the 9th Annual Oncology Nurse Advisor (ONA) Summit, which occurred from March 21-24, 2024.
  • New to the 2024 Summit was a one-day pre-conference Hematology Intensive on March 21 titled, What’s Blood Got to Do With It?
  • Also new to the Summit was the Real Solutions Virtual Poster Gallery, which presented real-life, innovative strategies and quality improvement solutions submitted by oncology nurses, which were selected for the Summit through a blind review by ONA Summit course directors.
  • Paula Anastasia, MN, RN, AOCN®, GYN Oncology Clinical Nurse Specialist, UCLA Health Sciences, participated in the Summit as Clinical Advisor, Peer Reviewer and Expert Moderator.

The Inner Circle acknowledges Nana E. Tchabo, MD, FACOG as a Pinnacle Life Member

Retrieved on: 
Thursday, March 7, 2024
Theta, Overlook Medical Center, Woman, Professional, Inner circle, Doctor of Philosophy, Multimedia, MD, Georgetown University, Education, Immunotherapy, Pathology, Thomas Jefferson University, Uterine cancer, ABOG, Parent, Principal investigator, Radiation, National Cancer Institute, Women's studies, Gynecologic Oncology (journal), Health, FACOG, Oncology nursing, Brown University, Vaginal cancer, Ovarian cancer, Associate, Gestational trophoblastic disease, Women's health, Biology, Mount Sinai School, Estate (law), Delta Sigma, Research, Carol, Medication

CHESTER, N.J., March 7, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Nana E. Tchabo, MD, FACOG, is acknowledged as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology.

Key Points: 
  • CHESTER, N.J., March 7, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Nana E. Tchabo, MD, FACOG, is acknowledged as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology.
  • Dr. Tchabo pursued higher education at Brown University where she received a Bachelor of Science in Neuroscience and a minor in Women's Studies.
  • She then attended the Warren Alpert Brown University School of Medicine, where she was cited for academic excellence.
  • Dr. Tchabo currently works at Atlantic Women's Cancer Associates, a part of Atlantic Health System Morristown and Overlook Medical Centers.

OVARIAN CANCER RESEARCH ALLIANCE CELEBRATES LANDMARK YEAR OF ACHIEVEMENTS IN 2023, SURPASSING FUNDRAISING GOALS AND ACCELERATING RESEARCH IN GYNECOLOGIC CANCERS

Retrieved on: 
Wednesday, January 17, 2024
Patient, Ovarian cancer, Research, Congress, OCRA, Life, Knowledge, Medicare, Data wrangling, Survivor, Cancer, Risk, Quality of life, Oncology nursing, Genetic testing, Human, Ovarian Cancer Research Alliance, Ovary, Diagnosis, Birth control

"Historically, 2023 has been a year of unparalleled achievement for OCRA," said Audra Moran, President and CEO.

Key Points: 
  • "Historically, 2023 has been a year of unparalleled achievement for OCRA," said Audra Moran, President and CEO.
  • "Our achievements this year have bolstered our commitment and energized our efforts to drive significant progress in understanding, preventing, and treating ovarian and related gynecologic cancers."
  • Recognizing the interconnectedness of ovarian and related gynecologic cancers, OCRA expanded its mission accelerating progress, acknowledging commonalities between these diseases, and broadening our impact on patients' lives.
  • Ovarian Cancer Research Alliance (OCRA) is the largest global organization dedicated to advancing ovarian cancer research while supporting patients and their families.

Florida Cancer Specialists & Research Institute Welcomes Gynecologic Oncologist Bradley Monk, MD, FACOG, FACS To Lead Late-Phase Clinical Research Program

Retrieved on: 
Wednesday, January 3, 2024
FACS, Cervical cancer, Research, Hope, MD, Health, Cancer, Standard of care, FACOG, FCS, Patient, Safety, Oncology nursing

FORT MYERS, Fla., Jan. 3, 2024 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) is pleased to announce that board-certified gynecologic oncologist Bradley Monk, MD, FACOG, FACS has joined the statewide practice. As medical director of the FCS Late-Phase Clinical Research Program, Dr. Monk will lead innovative initiatives to expand and deploy late-phase trials that are transforming cancer care worldwide. He is also providing care to patients at the FCS Palm Beach location, 1309 N. Flagler Drive, West Palm Beach, FL 33401.

Key Points: 
  • FORT MYERS, Fla., Jan. 3, 2024 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) is pleased to announce that board-certified gynecologic oncologist Bradley Monk, MD, FACOG, FACS has joined the statewide practice.
  • As medical director of the FCS Late-Phase Clinical Research Program, Dr. Monk will lead innovative initiatives to expand and deploy late-phase trials that are transforming cancer care worldwide.
  • "We are delighted to welcome Dr. Monk to our practice," said Lucio N. Gordan, MD , FCS President & Managing Physician.
  • Dr. Monk has extensive leadership experience in practice-changing clinical research and the development of clinical research programs in community oncology settings.

Northwell Opens $52M Cancer Center, Multispecialty Practice in Queens

Retrieved on: 
Tuesday, November 28, 2023
General Health, Hospitals, Health, Practice Management, Oncology, Queens Boulevard, Hindi, Oncology nursing, North Shore University Hospital, Gynaecology, Cancer Institute, LIJ, New Yorker, Head, Cardiology, Endocrinology, Genetic counseling, Surgical oncology, Hematology, Elective surgery, DEXA, Internal medicine, Urology, Breast cancer, Google Images, Patient, Multimedia, Gastrointestinal cancer, Colorectal surgery, Kimelman Cancer Institute, Neurology, Heart, Obstetrics, Rheumatology, MD Anderson Cancer Center, Rehabilitation, Bariatrics, Lung cancer screening, Gastroenterology, HIV, Neurosurgery, Cancer, QMA, MRI, Social work, Hospital, PET, General surgery, STARS, Estate (law), Nursing, Management, MD, Northwell Health

As part of the new cancer center, Queens Medical Associates (QMA), a member of the Northwell Health Cancer Institute, will move its highly regarded hematology and oncology practice, located in Fresh Meadows for over 30 years, to Rego Park.

Key Points: 
  • As part of the new cancer center, Queens Medical Associates (QMA), a member of the Northwell Health Cancer Institute, will move its highly regarded hematology and oncology practice, located in Fresh Meadows for over 30 years, to Rego Park.
  • Northwell treats about 19,000 New Yorkers with cancer each year, more than any other cancer provider in the state.
  • “We’re excited to open a new outpatient cancer center in the heart of Queens to deliver the best cancer care close to where people live,” said Richard Barakat, MD , physician-in-chief and executive director of the Northwell Health Cancer Institute.
  • “Northwell is uniquely positioned to care for patients in Queens – one of the most diverse places in the country.

Jemperli (dostarlimab for injection) plus carboplatin and paclitaxel approved in Canada as a treatment option for primary advanced or recurrent dMMR/MSI-H endometrial cancer

Retrieved on: 
Thursday, November 16, 2023
Orbis, Carboplatin, Paclitaxel, Priority review, Woman, Oncology nursing, Health Canada, Annual general meeting, SGO, Policy, Food, Platinum, Gynecologic Oncology (journal), US Foods, ESMO, Patient, Society of Gynecologic Oncology, Part, FDA, GOC, Endometrial cancer, Health, Standard of care, Cancer, CCSN, Survival, Partnership, Oncology, Society, MSI-H, Birth control, Pharmaceutical industry, Dostarlimab, MISSISSAUGA

Jemperli is the only immuno-oncology treatment approved for this patient population in combination with chemotherapy in Canada.

Key Points: 
  • Jemperli is the only immuno-oncology treatment approved for this patient population in combination with chemotherapy in Canada.
  • [1]
    "Today's approval supports our ambition for Jemperli to advance the standard of care for Canadian adult patients with primary advanced or recurrent dMMR/MSI-H endometrial cancer," said Marni Freeman, Country Medical Director at GSK Canada.
  • "This expanded approval of Jemperli offers a new care option to healthcare professionals treating this patient population with high unmet need."
  • "The CCSN is pleased to see a newly approved innovative treatment option for patients in Canada.

SAG-AFTRA PRESIDENT FRAN DRESCHER TO RECEIVE THE ROBERT F. KENNEDY HUMAN RIGHTS 2023 RIPPLE OF HOPE AWARD

Retrieved on: 
Tuesday, November 14, 2023
Bush, Social change, Policy, Select committee, Collective bargaining, State, Culture, Spirituality, Respect, Oncology nursing, Parent, Women's rights, Empathy, Government, Education

NEW YORK, Nov. 14, 2023 /PRNewswire/ -- Robert F. Kennedy Human Rights today announced that Fran Drescher, SAG-AFTRA president, actor, writer, and activist, will receive the 2023 Ripple of Hope Award in recognition of her leadership advocating for workers' rights.

Key Points: 
  • NEW YORK, Nov. 14, 2023 /PRNewswire/ -- Robert F. Kennedy Human Rights today announced that Fran Drescher, SAG-AFTRA president, actor, writer, and activist, will receive the 2023 Ripple of Hope Award in recognition of her leadership advocating for workers' rights.
  • The Robert F. Kennedy Ripple of Hope Award honors exemplary leaders across government, business, advocacy, and entertainment who have demonstrated an unwavering commitment to social change and worked to protect and advance equity, justice, and human rights.
  • "Robert F. Kennedy Human Rights has a long history of supporting union activity, and my father worked alongside union organizer Cesar Chavez to protect vulnerable farmworkers," said Kerry Kennedy, president of Robert F. Kennedy Human Rights.
  • "I am honored to be a recipient of the RFK Ripple of Hope Award," said Drescher.

The Inner Circle Acknowledges, Nana E. Tchabo, MD, FACOG as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology

Retrieved on: 
Monday, November 13, 2023
Theta, Inner circle, Georgetown University, Brown University, Woman, Oncology nursing, Associate, Reproductive Sciences, Research, Radiation, Cervical cancer, Gynecologic Oncology (journal), Overlook Medical Center, Pathology, National Cancer Institute, Roswell Park, Mount Sinai School, Women's studies, Multimedia, Professional, Fellow, Thomas Jefferson University, Vaginal cancer, Medication, Health, Alpert Medical School, Vulvar cancer, ABOG, Uterine cancer, Exceptional Women in Publishing, Ovarian cancer, MD, Japanese Cancer Association, FACOG, Delta Sigma, Women's health, Atlantic Women's Colleges Conference, Carol, Volunteering, Flexner Report, Estate (law), Biology, Education, Birth control, Science, Gynaecology, Medicine, Cancer, New York (magazine), Neuroscience, Obstetrics

CHESTER, N.J., Nov. 13, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Nana E. Tchabo, MD, FACOG, is acknowledged as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology.

Key Points: 
  • CHESTER, N.J., Nov. 13, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Nana E. Tchabo, MD, FACOG, is acknowledged as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology.
  • Dr. Tchabo pursued higher education at Brown University where she received a Bachelor of Science in Neuroscience, minoring in Women's Studies.
  • She then attended the Warren Alpert Medical School of Brown University for her medical degree, where she was cited for academic excellence.
  • Dr. Tchabo currently works at Atlantic Women's Cancer Associates, a part of Atlantic Health Systems Morristown and Overlook Medical Centers.

Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
Oncology, Health, Genetics, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Neoplasm, Research, PRS, Carboplatin, Ovarian cancer, Trae Waynes, Traveller Alien Module 2: K'kree, Oncology nursing, Partnership, CBR, September 5, ATR, CCNE1, Circulating tumor DNA, OR, BMS, Paclitaxel, Ono, Clinical Ovarian Cancer & Other Gynecologic Malignancies, Glomus tumor, Roche, Net, Safety, Therapy, Cancer, Patient, DNA, MRR, Conference, Clinical trial, Anemia, IST, AACR, Red Barricades: ASL Historical Module 1, FOLFIRI, Genotype, PPP2R1A, PKMYT1, FBXW7, Princess Margaret Cancer Centre, RECIST, Modularity, PARP, Pharmaceutical industry, Vaccine, Reinsurance, Reparenting, G&A, IND

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2023.
  • In the cohort of patients with gynecologic tumors, the RECIST response was 50%, OR was 60%, and CBR was 70%.
  • These patients also had a median of 3 and up to 9 prior lines of therapy, before administration of lunresertib.
  • RP-3467 is Repare’s wholly-owned Polθ inhibitor, currently in IND-enabling studies, which began in the second quarter of 2023 and remain ongoing.